Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over $20 billion.
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Kinnate Biopharma Inc's (NASDAQ: KNTE) board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company.
Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's (NYSE: NVO) popular diabetes medication, Ozempic,